EA201370139A1 - Ингибиторы микро-рнк, содержащие закрытые нуклеотиды - Google Patents
Ингибиторы микро-рнк, содержащие закрытые нуклеотидыInfo
- Publication number
- EA201370139A1 EA201370139A1 EA201370139A EA201370139A EA201370139A1 EA 201370139 A1 EA201370139 A1 EA 201370139A1 EA 201370139 A EA201370139 A EA 201370139A EA 201370139 A EA201370139 A EA 201370139A EA 201370139 A1 EA201370139 A1 EA 201370139A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- mir
- micro
- present
- oligonucleotides
- rnas
- Prior art date
Links
- 229940122938 MicroRNA inhibitor Drugs 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 108091092539 MiR-208 Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108091071651 miR-208 stem-loop Proteins 0.000 abstract 2
- 108091084446 miR-208a stem-loop Proteins 0.000 abstract 2
- 108091062547 miR-208a-1 stem-loop Proteins 0.000 abstract 2
- 108091055375 miR-208a-2 stem-loop Proteins 0.000 abstract 2
- 108091047268 miR-208b stem-loop Proteins 0.000 abstract 2
- 108091056170 miR-499 stem-loop Proteins 0.000 abstract 2
- 108091050885 miR-499-1 stem-loop Proteins 0.000 abstract 2
- 108091038523 miR-499-2 stem-loop Proteins 0.000 abstract 2
- 108091070501 miRNA Proteins 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/204—Modifications characterised by specific length of the oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42345610P | 2010-12-15 | 2010-12-15 | |
| US201161495224P | 2011-06-09 | 2011-06-09 | |
| PCT/US2011/065121 WO2012083005A2 (en) | 2010-12-15 | 2011-12-15 | Microrna inhibitors comprising locked nucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201370139A1 true EA201370139A1 (ru) | 2013-10-30 |
Family
ID=45771875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201370139A EA201370139A1 (ru) | 2010-12-15 | 2011-12-15 | Ингибиторы микро-рнк, содержащие закрытые нуклеотиды |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8642751B2 (enExample) |
| EP (1) | EP2652151A2 (enExample) |
| JP (1) | JP2014504857A (enExample) |
| KR (1) | KR20140004646A (enExample) |
| CN (1) | CN103380215A (enExample) |
| AR (1) | AR084319A1 (enExample) |
| AU (1) | AU2011343720A1 (enExample) |
| BR (1) | BR112013012319A2 (enExample) |
| CA (1) | CA2817371A1 (enExample) |
| EA (1) | EA201370139A1 (enExample) |
| MX (1) | MX2013005875A (enExample) |
| SG (1) | SG190355A1 (enExample) |
| WO (1) | WO2012083005A2 (enExample) |
| ZA (1) | ZA201303422B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817002C (en) | 2010-11-05 | 2019-01-15 | Miragen Therapeutics | Base modified oligonucleotides |
| CN103380215A (zh) * | 2010-12-15 | 2013-10-30 | 米拉根医疗公司 | 包含锁定核苷酸的微rna抑制剂 |
| JP6177243B2 (ja) | 2011-10-06 | 2017-08-09 | ミラゲン セラピューティクス， インコーポレイテッド | マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御 |
| DK3354734T3 (da) | 2012-06-21 | 2020-06-29 | Miragen Therapeutics Inc | Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster |
| AU2014233115B2 (en) | 2013-03-15 | 2019-08-01 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| WO2014151835A1 (en) * | 2013-03-15 | 2014-09-25 | Miragen Therapeutics, Inc | Locked nucleic acid inhibitor of mir-145 and uses thereof |
| WO2016022536A2 (en) | 2014-08-04 | 2016-02-11 | MiRagen Therapeutics, Inc. | Inhibitors of myh7b and uses thereof |
| US9885042B2 (en) | 2015-01-20 | 2018-02-06 | MiRagen Therapeutics, Inc. | miR-92 inhibitors and uses thereof |
| JP2018528967A (ja) * | 2015-09-22 | 2018-10-04 | ミラゲン セラピューティクス， インコーポレイテッド | Ｍｉｒ−１９調節物質およびその使用 |
| EP3181698A1 (en) | 2015-12-16 | 2017-06-21 | European Molecular Biology Laboratory (EMBL) | Microrna mir-142 as stem cell marker |
| WO2017187426A1 (en) | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
| EP3481404A4 (en) * | 2016-07-07 | 2020-03-25 | Miragen Therapeutics, Inc. | METHODS OF TREATING SKIN T LYMPHOMA (CT) WITH MIR-155 INHIBITORS |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| CN108220423A (zh) * | 2018-01-16 | 2018-06-29 | 新开源跃博（武汉）医疗科技有限公司 | 基于血浆miRNA的急性心梗快速诊断试剂及其在诊断试剂盒、评估方法中的应用 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US627170A (en) | 1899-06-20 | Tripod | ||
| US1159588A (en) | 1913-08-19 | 1915-11-09 | Jeddie Jubert | Fruit-picker. |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| AU7404994A (en) | 1993-07-30 | 1995-02-28 | Regents Of The University Of California, The | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| EP1012331B1 (en) | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| WO1999060855A1 (en) | 1998-05-26 | 1999-12-02 | Icn Pharmaceuticals, Inc. | Novel nucleosides having bicyclic sugar moiety |
| US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| AU3274500A (en) | 1999-03-18 | 2000-10-09 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
| ATE325806T1 (de) | 2000-10-04 | 2006-06-15 | Santaris Pharma As | Verbesserte synthese von purin-blockierten nukleinsäure-analoga |
| JP4371812B2 (ja) | 2001-09-28 | 2009-11-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | マイクロｒｎａ分子 |
| EP2298358A1 (en) | 2002-05-06 | 2011-03-23 | Alnylam Pharmaceuticals Inc. | Methods for delivery of nucleic acids |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| AU2005216564A1 (en) | 2004-02-26 | 2005-09-09 | Osprey Medical Inc. | Isolating cardiac circulation |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| EP2290072B1 (en) | 2004-05-28 | 2014-12-17 | Asuragen, Inc. | Methods and compositions involving microRNA |
| ES2534304T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| BRPI0608829A2 (pt) | 2005-04-19 | 2011-03-15 | Basf Plant Science Gmbh | método para a expressão transgênica com especificidade intensificada em uma planta, uso de um construto de ácido nucleico quimérico, seqüência de ribonucleotìdeo quimérica, construto de expressão, vetor de expressão, organismo não-humano ou célula transformada, semente transformada, e, preparação farmacêutica |
| SG162726A1 (en) | 2005-05-27 | 2010-07-29 | San Raffaele Centro Fond | Gene vector comprising mi-rna |
| PL1969125T3 (pl) | 2005-12-12 | 2012-11-30 | Univ North Carolina Chapel Hill | Mikrorna, które regulują proliferację i różnicowanie komórek mięśniowych |
| JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ， インコーポレーテッド | マイクロｒｎａの調節に使用するためのオリゴマー化合物及び組成物 |
| ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
| ES2397439T3 (es) * | 2006-08-01 | 2013-03-07 | Board Of Regents Of The University Of Texas System | Identificación de un microARN que activa la expresión de la cadena pesada beta de la miosina |
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| AU2007306594A1 (en) | 2006-10-09 | 2008-04-17 | Julius-Maximilians-Universitat Wurzburg | MicroRNA (miRNA) for the diagnosis and treatment of heart diseases |
| WO2008147430A2 (en) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Microrna-formatted multitarget interfering rna vector constructs and methods of using the same |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| EP2104733A2 (en) | 2006-12-14 | 2009-09-30 | Novartis AG | Compositions and methods to treat muscular and cardiovascular disorders |
| EP2113567B1 (en) | 2006-12-21 | 2019-04-03 | QIAGEN GmbH | MicroRNA target site blocking oligos and uses thereof |
| WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| WO2008131191A2 (en) * | 2007-04-20 | 2008-10-30 | Amgen Inc. | Nucleic acids hybridizable to micro rna and precursors thereof |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| US8481507B2 (en) | 2007-07-31 | 2013-07-09 | The Board Of Regents, The University Of Texas System | Micro-RNAs that control myosin expression and myofiber identity |
| EP2192925A4 (en) | 2007-08-23 | 2013-04-03 | Keren Pharmaceuticals | TARGETING RNA WITH EXTERNAL GUIDE SEQUENCES |
| JP5624470B2 (ja) | 2007-09-14 | 2014-11-12 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | ヒト末梢血微小胞におけるｍｉＲＮＡの発現およびその使用 |
| DK2205737T3 (da) | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Mikromirer |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| CN101424640B (zh) | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
| JP5654352B2 (ja) | 2007-11-09 | 2015-01-14 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | ｍｉＲ−１５ファミリーのマイクロＲＮＡによる心筋細胞生存及び心臓修復の調節 |
| US8404658B2 (en) | 2007-12-31 | 2013-03-26 | Nanocor Therapeutics, Inc. | RNA interference for the treatment of heart failure |
| EP2096171A1 (en) * | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| WO2009114681A2 (en) | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| CA2726052A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| US20110152352A1 (en) | 2008-06-10 | 2011-06-23 | Tufts University | Smad proteins control drosha-mediated mirna maturation |
| CN101386848A (zh) * | 2008-08-12 | 2009-03-18 | 南京大学 | 细胞微粒子所载微小核糖核酸及其制备研究方法和应用 |
| EP2346883B1 (en) | 2008-09-23 | 2016-03-23 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| MX2011008190A (es) * | 2009-02-04 | 2011-10-06 | Univ Texas | Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos. |
| WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| EA022757B1 (ru) * | 2009-06-08 | 2016-02-29 | Мираджен Терапьютикс | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК |
| US9078914B2 (en) | 2009-09-10 | 2015-07-14 | Velin-Pharma A/S | Method for the preparation of micro-RNA and its therapeutic application |
| EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| US8592151B2 (en) | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
| US20130109738A1 (en) | 2010-02-24 | 2013-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Control of Cardiac Growth, Differentiation and Hypertrophy |
| WO2011117353A1 (en) | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
| WO2011127625A1 (zh) | 2010-04-13 | 2011-10-20 | 江苏命码生物科技有限公司 | 一种调节生物体内微小核糖核酸含量的方法及其用途 |
| EP2865765B1 (en) | 2010-04-20 | 2016-08-17 | Hummingbird Diagnostics GmbH | Complex miRNA sets as novel biomarkers for an acute coronary syndrome |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| EP2580328A2 (en) | 2010-06-11 | 2013-04-17 | Cellartis AB | Micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types |
| ITMI20101089A1 (it) | 2010-06-16 | 2011-12-17 | Istituto Naz Di Genetica Molecolare Ingm | Profili di espressione di micro-rna nel sangue periferico per il monitoraggio del sistema immunitario |
| CA2804791C (en) | 2010-07-08 | 2019-07-30 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
| US20130137753A1 (en) | 2010-08-03 | 2013-05-30 | University Of South Alabama | Methods and compositions for the diagnosis and treatment of breast cancer |
| EP2603592A2 (en) | 2010-08-13 | 2013-06-19 | The University Court of the University of Glasgow | Therapeutic uses of microvesicles and related micrornas |
| WO2012027206A1 (en) | 2010-08-24 | 2012-03-01 | Merck Sharp & Dohme Corp. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
| CN103380215A (zh) * | 2010-12-15 | 2013-10-30 | 米拉根医疗公司 | 包含锁定核苷酸的微rna抑制剂 |
| WO2012149646A1 (en) | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Mirna inhibitors and their uses |
| JP6177243B2 (ja) | 2011-10-06 | 2017-08-09 | ミラゲン セラピューティクス， インコーポレイテッド | マイクロｒｎａの調節による全身エネルギーホメオスタシスの制御 |
| GB201117482D0 (en) | 2011-10-11 | 2011-11-23 | Univ Dundee | Targetiing of miRNA precursors |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| ES2897565T3 (es) | 2011-10-18 | 2022-03-01 | Dicerna Pharmaceuticals Inc | Lípidos catiónicos de amina y uso de los mismos |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン，インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| EP2604690A1 (en) | 2011-12-15 | 2013-06-19 | Oncostamen S.r.l. | MicroRNAs and uses thereof |
| EP2791337A1 (en) | 2011-12-15 | 2014-10-22 | Oncostamen S.r.l. | Micrornas and uses therof |
| FR2984358A1 (fr) | 2011-12-16 | 2013-06-21 | Genethon | Methodes pour le diagnostic de dystrophies musculaires |
| DK3354734T3 (da) * | 2012-06-21 | 2020-06-29 | Miragen Therapeutics Inc | Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster |
-
2011
- 2011-12-15 CN CN2011800674456A patent/CN103380215A/zh active Pending
- 2011-12-15 JP JP2013544772A patent/JP2014504857A/ja active Pending
- 2011-12-15 EP EP11820901.4A patent/EP2652151A2/en not_active Withdrawn
- 2011-12-15 BR BR112013012319A patent/BR112013012319A2/pt not_active IP Right Cessation
- 2011-12-15 MX MX2013005875A patent/MX2013005875A/es not_active Application Discontinuation
- 2011-12-15 AU AU2011343720A patent/AU2011343720A1/en not_active Abandoned
- 2011-12-15 WO PCT/US2011/065121 patent/WO2012083005A2/en not_active Ceased
- 2011-12-15 KR KR1020137015018A patent/KR20140004646A/ko not_active Withdrawn
- 2011-12-15 AR ARP110104716A patent/AR084319A1/es unknown
- 2011-12-15 US US13/327,507 patent/US8642751B2/en not_active Expired - Fee Related
- 2011-12-15 EA EA201370139A patent/EA201370139A1/ru unknown
- 2011-12-15 SG SG2013039003A patent/SG190355A1/en unknown
- 2011-12-15 CA CA2817371A patent/CA2817371A1/en not_active Abandoned
-
2013
- 2013-05-10 ZA ZA2013/03422A patent/ZA201303422B/en unknown
- 2013-12-16 US US14/107,784 patent/US20140187603A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2652151A2 (en) | 2013-10-23 |
| ZA201303422B (en) | 2014-07-30 |
| US8642751B2 (en) | 2014-02-04 |
| KR20140004646A (ko) | 2014-01-13 |
| BR112013012319A2 (pt) | 2019-09-24 |
| CN103380215A (zh) | 2013-10-30 |
| AR084319A1 (es) | 2013-05-08 |
| US20140187603A1 (en) | 2014-07-03 |
| CA2817371A1 (en) | 2012-06-21 |
| WO2012083005A2 (en) | 2012-06-21 |
| AU2011343720A1 (en) | 2013-04-11 |
| US20120184596A1 (en) | 2012-07-19 |
| JP2014504857A (ja) | 2014-02-27 |
| SG190355A1 (en) | 2013-07-31 |
| WO2012083005A3 (en) | 2012-08-16 |
| MX2013005875A (es) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201370139A1 (ru) | Ингибиторы микро-рнк, содержащие закрытые нуклеотиды | |
| EA201590070A1 (ru) | ИНГИБИТОРЫ МИКРОРНК СЕМЕЙСТВА miR-15 | |
| CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| EA201171493A1 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
| JOP20200115A1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
| UA118649C2 (uk) | ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR) | |
| EA201490042A1 (ru) | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| MX390699B (es) | Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3). | |
| MX359548B (es) | Agentes de iarn modificados. | |
| BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| EA202191537A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| MX2018013216A (es) | Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6). | |
| EA201101396A1 (ru) | Ингибиторы аутотаксина | |
| EA201391626A1 (ru) | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака | |
| EA201391329A1 (ru) | Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) | |
| BR112015023038A2 (pt) | composições para salto de exon para o tratamento da distrofia muscular | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
| MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
| EA201400311A1 (ru) | Аминозамещенные имидазопиридазины | |
| WO2019217397A3 (en) | Compositions and methods for improving strand biased | |
| WO2009090639A3 (en) | Sirna compounds and methods of use thereof |